Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product

Nicotine and Tobacco Research

Volumn 6, Issue 1, 2004, Pages 63-70

  D'Orlando, Kay J ^a,b   Fox, Barbara S ^a  

^a Recovery Pharmaceuticals Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; NICOTINE; NICOTINE GUM; NICOTINE TARTRATE; PLACEBO; THE STRAW;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; LIBIDO DISORDER; MALE; NAUSEA; NICOTINE REPLACEMENT THERAPY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING CESSATION; SNEEZING; STIMULATION; TOBACCO DEPENDENCE; VOMITING;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; COTININE; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SMOKING;

EID: 1642381888     PISSN: 14622203     EISSN: None     Source Type: Journal    
DOI: 10.1080/14622200310001656876     Document Type: Article

References (19)

1. Benowitz, N. L. (1988). Toxicity of nicotine: Implications with regard to nicotine replacement therapy. In O. F. Pomerleau & C. S. Pomerleau (Eds.), Nicotine replacement: A critical evaluation (pp. 187-217). New York: Liss.
2. Benowitz, N. L., Perez-Stable, E. J., Fong, I., Modin, G., Herrera, B., & Jacob, P., 3rd. (1999). Ethnic differences in N-glucuronidation of nicotine and cotinine. Journal of Pharmacology and Experimental Therapeutics, 291, 1196-1203.
3. Fiore, M., Bailey, W. C., Cohen, S., Dorfman, S., Goldstein, M., Gritz, E., Heyman, R., Jaén, C., Kottke, T., Lando, H., Mecklenburg, R., Mullen, P., Nett, L., Robinson, L., Stitzer, M., Tommasello, A., Villejo, L., & Wewers, M. (2000). Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service.
4. Hajek, P., West, R., Foulds, J., Nilsson, F., Burrows, S., & Meadow, A. (1999). Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Archives of Internal Medicine, 159, 2033-2038.
5. Hatsukami, D., Lexau, B., Nelson, D., Pentel, P. R., Sofuoglu, M., & Goldman, A. (1998). Effects of cotinine on cigarette self-administration. Psychopharmacology (Berlin), 138, 184-189.
6. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
7. Henningfield, J. E., Radzius, A., Cooper, T. M., & Clayton, R. R. (1990). Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. The Journal of the American Medical Association, 264, 1560-1564.
8. Hurt, R. D., Offord, K. P., Croghan, I. T., Croghan, G. A., Gomez-Dahl, L. C., Wolter, T. D., Dale, L. C., & Moyer, T. P. (1998). Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berlin), 140, 98-104.
9. Reid, R., Coyle, D., Papadakis, S., & Boucher, K. (2000). Nicotine replacement therapies in smoking cessation. Ottawa, Ontario, CA: Canadian Council on Tobacco Control.
10. Rose, J. E. (1996). Nicotine addiction and treatment. Annual Review of Medicine, 47, 493-507.
11. Schneider, N. G., Olmstead, R. E., Franzon, M. A., & Lunell, E. (2001). The nicotine inhaler: Clinical pharmacokinetics and comparison with other nicotine treatments. Clinical Pharmacokinetics, 40, 661-684.
12. Shiffman, S. M., & Jarvik, M. E. (1976). Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berlin), 50, 35-39.
13. Svensson, C. K. (1987). Clinical pharmacokinetics of nicotine. Clinical Pharmacokinetics, 12, 30-40.
14. U.S. Department of Health and Human Services. (2001). Women and smoking: A report of the surgeon general. Rockville, MD: Author, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
15. Westman, E. C., Roth, M., Tomlin, K., Bryson, W., & Rose, J. (2001a, March). Effect of an oral solution on plasma nicotine levels. Paper presented at the annual meeting of the Society for Research on Nicotine and Tobacco, Seattle, WA.
16. Westman, E. C., Tomlin, K. F., Perkins, C. E., & Rose, J. E. (2001b). Oral nicotine solution for smoking cessation: A pilot tolerability study. Nicotine & Tobacco Research, 3, 391-396.
17. Yankelovich Partners. (1998). Smoking cessation study. Norwalk, CT: Author. Retrieved August 13, 2003, from http://www.lungusa.org/partner/yank/l.html
18. Zevin, S., Jacob, P., Geppetti, P., & Benowitz, N. L. (2000). Clinical pharmacology of oral cotinine. Drug and Alcohol Dependence, 60, 13-18.
19. Zins, B. J., Sandborn, W. J., Mays, D. C., Lawson, G. M., McKinney, J. A., Tremaine, W. J., Mahoney, D. W., Zinsmeister, A. R., Hurt, R. D., Offord, K. P., & Lipsky, J. J. (1997). Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. Journal of Clinical Pharmacology, 37, 426-436.